newsfilter
← Latest News
PR Newswire·

Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

AZTA
  • Azenta reported Q4 2026 revenue growth of 5% year over year ($167 million) and 2% on an organic basis.
  • Full-year 2026 revenue grew 5% year over year to $622 million, with 2% organic growth.
  • Sample Management Solutions revenue increased 9% in Q4 2026 to $94 million, while Multiomics revenue remained flat at $73 million.
  • Full-year 2026 Sample Management Solutions revenue rose 6% to $344 million, and Multiomics revenue increased 3% to $277 million.
  • Diluted EPS from continuing operations was $0.14 for Q4 2026 and ($3.50) for the full year 2026.
  • Adjusted diluted EPS from continuing operations was $0.28 for Q4 2026 and $0.48 for the full year 2026.
  • Full-year 2026 Adjusted EBITDA was $58.3 million with a margin of 9.4%, a decrease of 180 basis points year over year.
  • The company completed the sale of B Medical Systems in July 2026, treating it as discontinued operations, and received $35 million plus interest in September 2026.
  • Fiscal 2027 total revenue is expected to range from $648 to $660 million with 3% to 5% organic growth.
  • Fiscal 2027 Adjusted EBITDA margin is projected to expand by 200 to 250 basis points year over year.
  • Azenta entered a Technology, Equipment and License Agreement with Elegen Corp. on October 28, 2026, for up to $71 million in aggregate capital deployment.
  • Azenta acquired SynPlexity Inc. on October 28, 2026, for a base price of $15 million with potential contingent consideration of up to $10 million.
  • During fiscal 2026, the company repurchased 4.4 million shares for $118.2 million under its 2025 Repurchase Program, leaving $131.8 million available.
  • Cash, cash equivalents, restricted cash, and marketable securities totaled $506 million as of September 30, 2026.
  • Full-year 2026 free cash flow was $27 million, with operating cash flow of $58 million and capital expenditures of $30 million.
  • A $149 million non-cash goodwill impairment charge was recorded in the second quarter of fiscal 2026, impacting full-year GAAP operating results.
Company
Azenta
Keywords
Azenta